Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Jun 17;14(1):13983.
doi: 10.1038/s41598-024-64476-9.

Association of blood group O with a recurrent risk for acute lower gastrointestinal bleeding from a multicenter cohort study

Sho Suzuki  1 , Naoyuki Tominaga  2 , Tomonori Aoki #  3 , Eiji Sadashima #  4 , Tadashi Miike  1 , Hiroshi Kawakami  1 , Katsumasa Kobayashi  5 , Atsushi Yamauchi  6 , Atsuo Yamada  3 , Jun Omori  7 , Takashi Ikeya  8 , Taiki Aoyama  9 , Yoshinori Sato  10 , Takaaki Kishino  11 , Naoki Ishii  12 , Tsunaki Sawada  13 , Masaki Murata  14 , Akinari Takao  15 , Kazuhiro Mizukami  16 , Ken Kinjo  17 , Shunji Fujimori  18 , Takahiro Uotani  19 , Minoru Fujita  20 , Hiroki Sato  21 , Toshiaki Narasaka  22   23 , Junnosuke Hayasaka  24 , Tomohiro Funabiki  25   26 , Yuzuru Kinjo  27 , Akira Mizuki  28 , Shu Kiyotoki  29 , Tatsuya Mikami  30 , Ryosuke Gushima  31 , Hiroyuki Fujii  32 , Yuta Fuyuno  33 , Takuto Hikichi  34 , Yosuke Toya  35 , Kazuyuki Narimatsu  36 , Noriaki Manabe  37 , Koji Nagaike  38 , Tetsu Kinjo  39 , Yorinobu Sumida  40 , Sadahiro Funakoshi  41 , Kiyonori Kobayashi  42 , Tamotsu Matsuhashi  43 , Yuga Komaki  44 , Mitsuru Kaise  7 , Naoyoshi Nagata  45   46
Affiliations
Multicenter Study

Association of blood group O with a recurrent risk for acute lower gastrointestinal bleeding from a multicenter cohort study

Sho Suzuki et al. Sci Rep. .

Abstract

The relationship between blood group and rebleeding in acute lower gastrointestinal bleeding (ALGIB) remains unclear. This study aimed to investigate the association between blood group O and clinical outcomes in patients with ALGIB. The study included 2336 patients with ALGIB whose bleeding source was identified during initial endoscopy (from the CODE BLUE-J Study). The assessed outcomes encompassed rebleeding and other clinical parameters. The rebleeding rates within 30 days in patients with blood group O and those without blood group O were 17.9% and 14.9%, respectively. Similarly, the rates within 1 year were 21.9% for patients with blood group O and 18.2% for those without blood group O. In a multivariate analysis using age, sex, vital signs at presentation, blood test findings, comorbidities, antithrombotic medication, active bleeding, and type of endoscopic treatment as covariates, patients with blood group O exhibited significantly higher risks for rebleeding within 30 days (odds ratio [OR] 1.31; 95% confidence interval [CI] 1.04-1.65; P = 0.024) and 1 year (OR 1.29; 95% CI 1.04-1.61; P = 0.020) compared to those without blood group O. However, the thrombosis and mortality rates did not differ significantly between blood group O and non-O patients. In patients with ALGIB, blood group O has been identified as an independent risk factor for both short- and long-term rebleeding.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Study flow chart SRH, stigmata of recent hemorrhage.
Figure 2
Figure 2
The cumulative probability of rebleeding using Kaplan–Meier method in acute lower gastrointestinal bleeding patients. (A) The cumulative probability of rebleeding within 30-day according to blood group (n = 2,336). (B) The cumulative probability of rebleeding within 1-year according to blood group (n = 2,336). * P-values were calculated using the Generalized Wilcoxon test.
Figure 3
Figure 3
The cumulative probability of rebleeding using Kaplan–Meier method in colonic diverticular bleeding patients. (A) The cumulative probability of rebleeding within 30-day according to blood group (n = 1,650). (B) The cumulative probability of rebleeding within 1-year according to blood group (n = 1,650). * P-values were calculated using the Generalized Wilcoxon test.
See this image and copyright information in PMC

References

    1. Radaelli F, et al. Clinical management and patient outcomes of acute lower gastrointestinal bleeding: A multicenter, prospective, cohort study. Dig Liver Dis. 2021;53:1141–1147. doi: 10.1016/j.dld.2021.01.002. - DOI - PubMed
    1. Oakland K, et al. Acute lower GI bleeding in the UK: patient characteristics, interventions and outcomes in the first nationwide audit. Gut. 2018;67:654–662. - PubMed
    1. Niikura R, et al. Efficacy and safety of early vs elective colonoscopy for acute lower gastrointestinal bleeding. Gastroenterology. 2020;158:168–175.e6. doi: 10.1053/j.gastro.2019.09.010. - DOI - PubMed
    1. Aoki T, et al. Development and validation of a risk scoring system for severe acute lower gastrointestinal bleeding. Clin. Gastroenterol. Hepatol. 2016;14:1562–1570.e2. doi: 10.1016/j.cgh.2016.05.042. - DOI - PubMed
    1. Lanas A, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am. J. Gastroenterol. 2007;102:507–515. doi: 10.1111/j.1572-0241.2006.01062.x. - DOI - PubMed

Publication types

Substances